关于对蒋淑霞、王兴杰、乔鑫采取出具警示函行政监管措施的决定（利安达广誉远年审项目）

Core Viewpoint - The audit of Guangyuyuan Traditional Chinese Medicine Co., Ltd. from 2016 to 2018 revealed significant deficiencies in the auditing processes, leading to insufficient evidence and inappropriate conclusions regarding revenue recognition and sales expenses [1][2][3][4][5] Group 1: Revenue Audit Issues - The audit tests for revenue from 2016 to 2018 were inadequately executed, resulting in insufficient audit evidence [1] - Interviews conducted during the audit did not adequately consider the impact of return and payment terms on revenue recognition, nor did they address discrepancies in reported sales figures [1][2] - Contract checks were superficial, failing to identify critical clauses affecting revenue recognition and not verifying the actual inventory and sales situation of downstream commercial companies [2] - Sampling procedures for document verification were not followed as planned, leading to incomplete data and inconsistent information across business documents [2][3] - The audit did not adequately address issues related to returns, including incomplete documentation and non-compliance with contractual return conditions [3] Group 2: Sales Expense Audit Issues - The audit of advertising expenses in 2018 lacked thorough verification of contracts and supporting documents, leading to unsubstantiated conclusions about the accuracy of expense recognition [4] Group 3: Regulatory Violations and Consequences - The auditors' actions violated several auditing standards and regulations, leading to a warning letter issued by the Beijing Securities Regulatory Bureau [5] - The auditors involved, including Jiang Shuxia, Wang Xingjie, and Qiao Xin, are held primarily responsible for the identified issues and face regulatory measures [5]